cept Therapeutics rporated(CORT) - 2024 Q1 - Quarterly Results

EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE The company increased its 2024 revenue guidance to $620 – $650 million. Clinical Development "The results of the open-label phase of our GRACE trial, which we released last week, are compelling," said Dr. Belanoff. "We expect to build on these results in the trial's randomized withdrawal phase. Results from this portion of the study will be available in the coming weeks. We are on track to submit our ND ...